AusBiotech secures Australian first with world brain mapping congress
14 May, 2013AusBiotech is pleased to announce that the 11th Annual World Congress of the Society for Brain Mapping and Therapeutics (SBMT) will be held in Australia for the first time in March 2014.
Bioniche to sell animal health division
14 May, 2013 by Dylan Bushell-EmblingBioniche (ASX:BNC) has hired an adviser to help it negotiate a sale of its animal health division and has received two preliminary partnership offers for bladder cancer treatment Urocidin.
Mercury Capital invests in Novotech
14 May, 2013 by Dylan Bushell-EmblingPE firm Mercury Capital has acquired a 30% stake in incumbent Australian CRO Novotech, with the option to increase its holding to 50%.
AU boffins develop bacteria-killing Trojan horse
13 May, 2013 by Dylan Bushell-EmblingScientists from UOW and UNSW have patented a new drug technology for combating antibiotic-resistant bacteria, developed by thinking like the enemy.
BioDiem moves to animal trials in pneumocystosis
13 May, 2013 by Dylan Bushell-EmblingBioDiem (ASX:BDM) has said its antimicrobial candidate BDM-I is ready for preclinical trials against Pneumocystosis, a parasitic fungus that can cause pneumonia.
Starpharma dendrimer effective against adenovius
13 May, 2013 by Dylan Bushell-EmblingStarpharma (ASX:SPL) said its lead dendrimer candidate has shown potential as the first treatment for adenovirus, the primary cause of viral conjunctivitis.
Cellmid to buy Advangen Japan in $4m deal
10 May, 2013 by Dylan Bushell-EmblingCellmid (ASX:CDY) will pay around $4m in cash and stock to acquire Advangen Japan and, with it, the hair growth technology platform behind Cellmid’s evolis line.
Bioniche in talks to boost cash reserves
09 May, 2013 by Dylan Bushell-EmblingBioniche (ASX:BNC) is in talks with its lender to address a looming cash shortage and consulting with advisers to address the “challenges” posed by a group of dissident shareholders.
Concern over NSW indemnity insurance impact on clinical trials prompts survey
09 May, 2013Members of AusBiotech are invited to participate in a survey to gauge the impact of the 2011 increase in the Clinical Trial Indemnity Insurance Compliance Requirement.
New member for Prima board
09 May, 2013 by Susan Williamson and Dylan Bushell-EmblingPrima Biomed (ASX: PRR) has announced a new board member, Dr Russell Howard.
Iluvien launches in Germany
08 May, 2013 by Dylan Bushell-EmblingpSivida (ASX:PVA) licensee Alimera Sciences has followed up the launch of DME treatment Iluvien in the UK with the first commercial sale in Germany.
Novogen appoints new CSO
07 May, 2013 by Dylan Bushell-EmblingNovogen (ASX:NRT) has announced two new executive appointments - a CSO, as well as a president and CEO of its new North American subsidiary.
Submission to reduce clinical trial insurance in NSW
07 May, 2013 by Susan WilliamsonContributions are being sought for a submission to NSW Health to reduce clinical trial indemnity insurance in the state.
Japan’s I’rom buys into IDT Australia
07 May, 2013 by Dylan Bushell-EmblingJapanese site management organisation (SMO) I’rom Holdings will pay $2m for a 19% stake in CMO IDT Australia, and the pair will combine their clinical trial site offerings in Australasia.
David Penington to headline AusMedtech Melbourne conference dinner
07 May, 2013Emeritus Professor David Penington AC will deliver an insightful address about his experiences within the medical industry and how to translate medical research into products as part of the AusMedtech 2013 conference dinner on Wednesday 15 May 2013.
